The trial tested six injectable doses and three oral doses over as long as 36 weeks
Surgical site infections and antimicrobial resistance remain major challenges globally
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
A key highlight will be Brenntag’s qualified amino acids portfolio
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Subscribe To Our Newsletter & Stay Updated